scispace - formally typeset
J

Jason E. Cain

Researcher at Hudson Institute of Medical Research

Publications -  81
Citations -  2754

Jason E. Cain is an academic researcher from Hudson Institute of Medical Research. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 24, co-authored 62 publications receiving 1998 citations. Previous affiliations of Jason E. Cain include Monash Institute of Medical Research & Hudson Institute.

Papers
More filters
Journal ArticleDOI

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.
Journal ArticleDOI

Hedgehog Signaling in the Maintenance of Cancer Stem Cells

TL;DR: The mounting evidence suggestive of Hh-driven CSCs in the context of haematological malignancies and solid tumours is discussed and the novel strategies that hold the potential to block many aspects of the transformation attributed to the CSC phenotype, including chemotherapeutic resistance, relapse and metastasis are discussed.
Journal ArticleDOI

Hedgehog stimulates hair follicle neogenesis by creating inductive dermis during murine skin wound healing

TL;DR: The authors show that if Sonic hedgehog signaling is activated in the wound, an inductive dermal niche forms, enabling regeneration and hair follicle formation, demonstrating that mechanisms of scarring and regeneration are not distant from one another and that wound repair can be redirected to promote regeneration following injury by modifying a key dermal signal.
Journal ArticleDOI

Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

TL;DR: Overall, this work shows how liposomal encapsulation of irinotecan can safely improve its antitumor activity in preclinical models by enhancing accumulation of its active metabolite within the tumor microenvironment.
Journal ArticleDOI

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

TL;DR: Correlation between FMX levels in tumor lesions and nal-IRI activity suggests that lesion permeability to FMX and subsequent tumor uptake may be a useful noninvasive and predictive biomarker for nal -IRI response in patients with solid tumors.